Next-generation peptide vaccines for advanced cancer

Yamada, Akira; Sasada, Tetsuro; Noguchi, Masanori; Itoh, Kyogo

doi:10.1111/cas.12050

Cited by 124Immunotherapy and Immune Responsesvaccines and immunoinformatics approachesChemical Synthesis and Analysis

Next-generation peptide vaccines for advanced cancer

Open access

Yamada, Akira, Sasada, Tetsuro, Noguchi, Masanori, Itoh, Kyogo·2013·Cancer Science

DOI 10.1111/cas.12050PMC PMC7657262

Open this paper in CoChat — free account Open PDF

Abstract

Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a melanoma antigen gene‐1‐derived peptide‐based vaccine was reported in 1995. The earlier generations of peptide vaccines were composed of one to several human leukocyte antigen class I‐restricted CTL‐epitope peptides of a single human leukocyte antigen type. Currently, various types of next‐generation peptide vaccines are under development. In this review, we focus on the clinical trials of the following categories of peptide vaccines mainly published from 2008 to 2012: (i) multivalent long peptide vaccines; (ii) multi‐peptide vaccines consisting of CTL‐ and helper‐epitopes; (iii) peptide cocktail vaccines; (iv) hybrid peptide vaccines; (v) personalized peptide vaccines; and (vi) peptide‐pulsed dendritic cell vaccines. (Cancer Sci 2013; 104: 15–21)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/cas.12050

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical trials of peptide vaccines have shown mixed results even though the overall trend was positive.
“However, clinical trials have shown mixed results even though the overall trend was positive [155,156].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [155]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548 · see citing works
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y., Scanlan, M. J., Şahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M. G., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247 · see citing works
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,101 · see citing works
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C. A., Staehler, M. D., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788 · see citing works
Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Okada, H., Kaliński, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 570 · see citing works
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
Alexander, J., Sidney, J., Southwood, S., et al. (1994) · Immunity · doi:10.1016/s1074-7613(94)80017-0 · Cited by 525 · see citing works
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 316 · see citing works
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M. S., Bogle, D., Yan, L. E., Targan, S., Solomon, J. C., Nichol, G. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 200 · see citing works
Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185 · see citing works
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese‐Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171 · see citing works
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting
Slingluff, C. L., Petroni, G. R., Chianese‐Bullock, K. A., Smolkin, M. E., Hibbitts, S., Murphy, C., Johansen, N., Grosh, W. W., Yamshchikov, G. V., Neese, P. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0486 · Cited by 163 · see citing works
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
Maslak, P. G., Dao, T., Krug, L. M., Chanel, S. M., Korontsvit, T., Zakhaleva, V., Zhang, R., Wolchok, J. D., Yuan, J. D., Pinilla-Ibarz, J. A., et al. (2010) · Blood · doi:10.1182/blood-2009-10-250993 · Cited by 154 · see citing works
Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
Hu, X., Chakraborty, N. G., Sporn, J., et al. (1996) · PubMed · Cited by 151 · see citing works
Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/ neu Peptide (AE37) Vaccine
Holmes, J. P., Benavides, L. C., Gates, J. D., Carmichael, M. G., Hueman, M. T., Mittendorf, E. A., Murray, J. L., Amin, A., Craig, D., Hofe, E. V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7842 · Cited by 137 · see citing works
Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma
Yajima, N., Yamanaka, R., Mine, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0559 · Cited by 134 · see citing works
Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme
Terasaki, M., Shibui, S., Narita, Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7499 · Cited by 123 · see citing works
Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
Slingluff, C. L., Petroni, G. R., Chianese‐Bullock, K. A., Smolkin, M. E., Ross, M. I., Haas, N. B., von Mehren, M., & Grosh, W. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8053 · Cited by 123 · see citing works
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
Krug, L. M., Dao, T., Brown, A. B., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0871-8 · Cited by 122 · see citing works
A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer
Chianese‐Bullock, K. A., Irvin, W. P., Petroni, G. R., Murphy, C., Smolkin, M. E., Olson, W. C., Coleman, E. J., Boerner, S. A., Nail, C. J., Neese, P. Y., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816dad10 · Cited by 111 · see citing works
Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer
Feyerabend, S., Stevanović, S., Gouttefangeas, C., et al. (2009) · The Prostate · doi:10.1002/pros.20941 · Cited by 108 · see citing works
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Rahma, O. E., Ashtar, E., Czystowska, M., Szajnik, M. E., Wieckowski, E. U., Bernstein, S. A., Herrin, V. E., Shams, M. A., Steinberg, S. M., Merino, M. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1100-9 · Cited by 104 · see citing works
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Svane, I. M., Pedersen, A. E., Johansen, J. S., Johnsen, H. E., Nielsen, D. L., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0293-4 · Cited by 104 · see citing works
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination
Noguchi, M., Kobayashi, K., Suetsugu, N., et al. (2003) · The Prostate · doi:10.1002/pros.10276 · Cited by 104 · see citing works
Self-citation
Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides
Kavanagh, B. D., Ko, A. H., Venook, A. P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318133451c · Cited by 103 · see citing works
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
Noguchi, M., Kakuma, T., Uemura, H., Nasu, Y., Kumon, H., Hirao, Y., Moriya, F., Suekane, S., Matsuoka, K., Komatsu, N., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0822-4 · Cited by 101 · see citing works
Self-citation
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer
Barve, M. A., BENDER, J. G., Senzer, N. N., Cunningham, C. C., Greco, F. A., McCune, D. E., Steis, R. G., Khong, H. T., Richards, D., Stephenson, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6462 · Cited by 100 · see citing works
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
Yuan, J. D., Ginsberg, B., Page, D. B., Li, Y., Rasalan, T. S., Gallardo, H. F., Xu, Y., Adams, S., Bhardwaj, N., BUSAM, K. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1011-9 · Cited by 94 · see citing works
Personalized peptide vaccines: A new therapeutic modality for cancer
Itoh, K., & Yamada, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00272.x · Cited by 85 · see citing works
Self-citation
A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen
Kakimi, K., Isobe, M., Uenaka, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25955 · Cited by 83 · see citing works
Recent Advances in Cancer Vaccines: An Overview
Itoh, K., Yamada, A., Mine, T., & Noguchi, M. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn132 · Cited by 76 · see citing works
Self-citation
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
Kuball, J. H. E., de Boer, K., Wagner, E. M., Wattad, M. A., Antunes, E., Weeratna, R. D., Vicari, A. P., Lotz, C., van Dorp, S., Hol, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0929-7 · Cited by 74 · see citing works
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients
Noguchi (2010) · Oncology Reports · doi:10.3892/or_00000923 · Cited by 74 · see citing works
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre‐existing cellular response to peptide
Sato, Y., Shomura, H., Maeda, Y., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01522.x · Cited by 70 · see citing works
Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers
Tsuda, N., Mochizuki, K., Harada, M., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200401000-00006 · Cited by 69 · see citing works
Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Perez, S. A., Kallinteris, N. L., Bisias, S., Tzonis, P., Georgakopoulou, K., Varla-Leftherioti, M., Papamichail, M., Thanos, A., Hofe, E. V., & Baxevanis, C. N. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0085 · Cited by 65 · see citing works
First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen
Takahashi, N., Ohkuri, T., Homma, S., Ohtake, J., Wakita, D., Togashi, Y., Kitamura, H., Todo, S., & Nishimura, T. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02106.x · Cited by 61 · see citing works
Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer
Leffers, N., Vermeij, R., Hoogeboom, B., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.25980 · Cited by 60 · see citing works
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S., & Matsuoka, K. (2004) · The Prostate · doi:10.1002/pros.20157 · Cited by 58 · see citing works
Self-citation
Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients
Mine, T., Gouhara, R., Hida, N., Imai, N., Azuma, K., Rikimaru, T., Katagiri, K., Nishikori, M., Sukehiro, A., Nakagawa, M., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01481.x · Cited by 56 · see citing works
Self-citation
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer
Yanagimoto, H., Mine, T., Yamamoto, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00429.x · Cited by 54 · see citing works
Immunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients
Sato, Y., Fujiwara, T., Mine, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00498.x · Cited by 50 · see citing works
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
Sato, Y., Maeda, Y., Shomura, H., Sasatomi, T., Takahashi, M., Une, Y., Kondo, M., Shinohara, T., Hida, N., Katagiri, K., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601711 · Cited by 48 · see citing works
Self-citation
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
Noguchi, M., Yao, A., Harada, M., et al. (2007) · The Prostate · doi:10.1002/pros.20572 · Cited by 47 · see citing works
Self-citation
Phase II study of personalized peptide vaccination for castration‐resistant prostate cancer patients who failed in docetaxel‐based chemotherapy
Noguchi, M., Moriya, F., Suekane, S., Matsuoka, K., Arai, G., Matsueda, S., Sasada, T., Yamada, A., & Itoh, K. (2011) · The Prostate · doi:10.1002/pros.21485 · Cited by 43 · see citing works
Self-citation
Personalized peptide vaccination in patients with refractory non-small cell lung cancer
Sasada, T. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1351 · Cited by 42 · see citing works
Self-citation
MHC Class I–Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer
Morse, M. A., Secord, A. A., Blackwell, K., Hobeika, A. C., Sinnathamby, G., Osada, T., Hafner, J., Philip, M., Clay, T. M., Lyerly, H. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2614 · Cited by 41 · see citing works
Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery
Tanaka, S., Harada, M., Mine, T., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00008 · Cited by 41 · see citing works
Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer
Noguchi, M., Itoh, K., Suekane, S., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03174.x · Cited by 38 · see citing works
Self-citation
A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer
Noguchi, M., Uemura, H., Naito, S., et al. (2010) · The Prostate · doi:10.1002/pros.21261 · Cited by 38 · see citing works
Self-citation
A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin
Matsumoto, K., Noguchi, M., Satoh, T., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09933.x · Cited by 36 · see citing works
Self-citation
Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients
Suekane, S., Nishitani, M., Noguchi, M., Komohara, Y., Kokubu, T., Naitoh, M., Honma, S., Yamada, A., Itoh, K., Matsuoka, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00631.x · Cited by 36 · see citing works
Self-citation
Combination Therapy of Personalized Peptide Vaccination and Low-Dose Estramustine Phosphate for Metastatic Hormone Refractory Prostate Cancer Patients: An Analysis of Prognostic Factors in the Treatment
Noguchi, M., Mine, T., Yamada, A., et al. (2006) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000006783980955 · Cited by 36 · see citing works
Self-citation
Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines
Kallinteris, N. L., Lu, X., Blackwell, C. E., et al. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1311 · Cited by 28 · see citing works
Immunological monitoring during combination of patient‐oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
Noguchi, M., Itoh, K., Suekane, S., et al. (2004) · The Prostate · doi:10.1002/pros.20011 · Cited by 27 · see citing works
Self-citation
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer
Meyer, R. G., Korn, S., Micke, P., Becker, K., Huber, C., Wölfel, T., & Buhl, R. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.003 · Cited by 25 · see citing works
Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer
Terazaki, Y., Yoshiyama, K., Matsueda, S., Watanabe, N., Kawahara, A., Naito, Y., Suekane, S., Komatsu, N., Ioji, T., Yamada, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02202.x · Cited by 24 · see citing works
Self-citation
Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
吉山, 康. (2013) · Kurume University Institutional Repository (Kurume University) · Cited by 17 · see citing works

Flagged first, then by citations

Sorted by citations

Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597 · see citing works
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS
Tomiyama, H., Miwa, K., Shiga, H., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.5026 · Cited by 81 · see citing works
Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1
Ikeda-Moore, Y., Tomiyama, H., Miwa, K., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.12.6242 · Cited by 100 · see citing works
Design of a cell-penetrating peptide vaccine based on HPV16 E7 epitope and its immunologic effect invitro
Yang, X. (2005) · Linchuang pifuke zazhi
Identification of B and T Cell Epitopes to Design an Epitope-Based Peptide Vaccine against the Cell Surface Binding Protein of Monkeypox Virus: An Immunoinformatics Study
Mazumder, L., Hasan, M. R., Fatema, K., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/2274415 · Cited by 12 · see citing works
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies
Chianese‐Bullock, K. A., Lewis, S. T., Sherman, N. E., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.018 · Cited by 27 · see citing works

Authors: Yamada, A., Sasada, T., Noguchi, M., & Itoh, K.
Affiliations: Kurume University (JP)
Corresponding author: Yamada, Akira
ORCID: Yamada, Akira
Sasada, Tetsuro
Noguchi, Masanori
Venue: Cancer Science
Publisher: Wiley
Published: 2012-12-04
Volume: 104
Issue: 1
Pages: 15-21
ISSN: 1347-9032 (ISSN-L)
1349-7006
DOI: 10.1111/cas.12050
PMC: PMC7657262
OpenAlex: W1981553458
Cited by: 124
References: 58
Citations by year: 2025: 4 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 17 · 2015: 18 · 2014: 13 · 2013: 12
FWCI: 1.27
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer Science (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Japan Society for the Promotion of Science (23501292)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
Keywords: peptide vaccine, cancer immunotherapy, CTL epitopes, HLA class I restriction, multipeptide vaccine, helper T cell epitopes, personalized peptide vaccine, dendritic cell vaccine, peptide-pulsed dendritic cells, advanced cancer, clinical trials
MeSH terms: Antigens, Neoplasm, Dendritic Cells, Humans, Neoplasms, T-Lymphocytes, Cytotoxic, Vaccines, Synthetic, Histocompatibility Antigens Class I, Epitopes, T-Lymphocyte, Cancer Vaccines, Vaccines, Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Next-generation peptide vaccines for advanced cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks